Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Follow up complete |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1 trial to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of HIV-1 nef/tat/vif, env pDNA vaccine delivered intramuscularly with electroporation and HIV-1 rVSV envC vaccine in healthy HIV-uninfected adult participants
Description
HVTN 112 is a Phase I clinical trial to evaluate the safety and immunogenicity of a prime/boost regimen using HIV-1 nef/tat/vif, env pDNA via electroporation and HIV-1 rVSV envC.
Sign in to see full information about this study and to download study data.
Products
Saline (NaCl) VSV HIV envC HIV-1 nef/tat/vif, env pDNAIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.